Literature DB >> 10361728

Changes during subclone development and ageing of human antibody-producing recombinant CHO cells.

K Strutzenberger1, N Borth, R Kunert, W Steinfellner, H Katinger.   

Abstract

Some of the problems encountered with human or human-mouse heterohybridomas, such as low growth rates and high serum requirements, have led to the increased use of recombinant cell lines for production of human antibodies. To evaluate the suitability of such alternative cell lines for the production of human antibodies we have analysed several subclones with differing specific production rates of a recombinant CHO cell line. Gene copy number and site of chromosomal integration for the light and heavy chain and the dhfr gene were determined by in-situ hybridisation. Specific mRNA content was analysed by Northern blot. In addition the intracellular content in light and heavy chain was measured by flow cytometry and the specific secretion rates were determined. The stability of gene expression was followed in the highest producing subclone for over a year. As previously seen in heterohybridoma cells a high expression rate of light chain is beneficial in speeding up secretion rates of whole antibody. When grown in the presence of G418 and methotrexate the amplified gene copies in the genome of recombinant CHO cells were stable over more than 100 passages. However, the expression of light chain, and with it the secretion rate, decreased with time. The low intracellular concentration of light chain resulted in accumulation of heavy chain in the endoplasmic reticulum due to retention by chaperones. The specific secretion rate decreased by 50% after 100 passages. When no G418 or methotrexate were present 75% of the gene copies were lost after 100 passages.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10361728     DOI: 10.1016/s0168-1656(99)00044-9

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  7 in total

1.  Impact of using different promoters and matrix attachment regions on recombinant protein expression level and stability in stably transfected CHO cells.

Authors:  Steven C L Ho; Jessna H M Yeo; Shiyi Goh Fang; Yuansheng Yang
Journal:  Mol Biotechnol       Date:  2015-02       Impact factor: 2.695

2.  Identification of transgene integration loci of different highly expressing recombinant CHO cell lines by FISH.

Authors:  Christine Lattenmayer; Martina Loeschel; Willibald Steinfellner; Evelyn Trummer; Dethardt Mueller; Kornelia Schriebl; Karola Vorauer-Uhl; Hermann Katinger; Renate Kunert
Journal:  Cytotechnology       Date:  2006-11-15       Impact factor: 2.058

3.  CRISPR/Cas9-mediated gene knockout for DNA methyltransferase Dnmt3a in CHO cells displays enhanced transgenic expression and long-term stability.

Authors:  Yan-Long Jia; Xiao Guo; Jiang-Tao Lu; Xiao-Yin Wang; Le-Le Qiu; Tian-Yun Wang
Journal:  J Cell Mol Med       Date:  2018-05-30       Impact factor: 5.310

4.  Intraclonal protein expression heterogeneity in recombinant CHO cells.

Authors:  Warren Pilbrough; Trent P Munro; Peter Gray
Journal:  PLoS One       Date:  2009-12-23       Impact factor: 3.240

5.  Evaluating the use of a CpG free promoter for long-term recombinant protein expression stability in Chinese hamster ovary cells.

Authors:  Steven C L Ho; Esther Y C Koh; Benjamin P C Soo; Sheng-Hao Chao; Yuansheng Yang
Journal:  BMC Biotechnol       Date:  2016-10-18       Impact factor: 2.563

6.  Evaluating the efficiency of CHEF and CMV promoter with IRES and Furin/2A linker sequences for monoclonal antibody expression in CHO cells.

Authors:  Saeedeh Ebadat; Samira Ahmadi; Maryam Ahmadi; Fatemeh Nematpour; Farzaneh Barkhordari; Reza Mahdian; Fatemeh Davami; Fereidoun Mahboudi
Journal:  PLoS One       Date:  2017-10-12       Impact factor: 3.240

7.  Fluorescence-assisted sequential insertion of transgenes (FASIT): an approach for increasing specific productivity in mammalian cells.

Authors:  Felipe E Bravo; Natalie C Parra; Frank Camacho; Jannel Acosta; Alaín González; Jorge R Toledo; Oliberto Sanchez
Journal:  Sci Rep       Date:  2020-07-30       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.